Intelligent Bio Solutions Grants Equity Awards, Updates ATM Capacity

The latest update is out from Intelligent Bio Solutions ( (INBS) ).

On March 18, 2026, Intelligent Bio Solutions granted time- and performance-vesting restricted stock to its directors, officers and employees under its 2019 Long Term Incentive Plan, including sizable awards to its CEO and CFO that vest over four years and upon the achievement of specified clinical trial, FDA regulatory, and commercial milestones. The company also adopted new jurisdiction-specific award agreement forms for U.S., U.K. and Australian participants, issued additional shares to directors and non-executive employees, and reported that total common shares outstanding reached 2,001,173 as of March 23, 2026.

Separately, the company provided an update on its at-the-market equity offering, noting that as of March 23, 2026, it had $3,966,316 of additional common stock capacity available to be sold under its existing Form S-3 shelf registration and ATM Agreement, supported by a new 2026 prospectus supplement. These moves underscore the company’s continued use of equity-based incentives to align management and staff with long-term performance goals while preserving financial flexibility through an established ATM program for future capital needs.

The most recent analyst rating on (INBS) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Intelligent Bio Solutions stock, see the INBS Stock Forecast page.

Spark’s Take on INBS Stock

According to Spark, TipRanks’ AI Analyst, INBS is a Neutral.

The score is held down primarily by very large losses and sustained negative free cash flow, alongside a clearly bearish price trend. Offsetting factors include improving revenue/gross margin, manageable leverage, and positive corporate developments (manufacturing scale/cost initiatives, FDA-oriented clinical work, and added financing runway).

To see Spark’s full report on INBS stock, click here.

More about Intelligent Bio Solutions

Intelligent Bio Solutions Inc. operates in the biotechnology and medical technology sector, focusing on products that require clinical trials, regulatory approvals and commercial supply and sales infrastructure, as indicated by its use of performance milestones tied to clinical, regulatory, and commercial achievements. The company accesses capital markets via an at-the-market equity offering program, using a shelf registration to issue common stock as needed for funding and growth initiatives.

Average Trading Volume: 2,515,394

Technical Sentiment Signal: Sell

Current Market Cap: $5.5M

For an in-depth examination of INBS stock, go to TipRanks’ Overview page.